Box 36
Container
Contains 19 Results:
Respiratory and Anesthetic Drugs Advisory Committee, 1966-1969
File — Box: 36, Folder: 1
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1966-1969
Respiratory and Anesthetic Drugs Committee: Doxapram, 1968
File — Box: 36, Folder: 2
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1968
Respiratory and Anesthetic Drugs Committee: Fluoramar, 1968
File — Box: 36, Folder: 3
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1968
Respiratory and Anesthetic Drugs Committee: Halothane, 1967
File — Box: 36, Folder: 4
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1967
Respiratory and Anesthetic Drugs Committee: Penthrane, 1967, 1969
File — Box: 36, Folder: 5
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1967, 1969
Review Committee of the Task Force on Prescription Drugs, 1967-1969
File — Box: 36, Folder: 6
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1967-1969
Review Committee of the Task Force on Prescription Drugs: comments of members: Adriani-Hutton, 1969
File — Box: 36, Folder: 7
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1969
Review Committee of the Task Force on Prescription drugs: comments of members: Mattia-Zimmer, 1969
File — Box: 36, Folder: 8
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1969
Clark, Margaret A., 1968-1970
File — Box: 36, Folder: 10
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1968-1970
de Haen, Paul, 1970-1971
File — Box: 36, Folder: 11
Scope and Contents
From the Series:
The Pharmaceutical Evaluations and Consulting Series contains material Adriani accumulated during his service as a pharmaceutical consultant to the federal government (especially to the Food and Drug Administration), to private organizations such as the American Medical Association (AMA) and its Council on Drugs, and to private industry. The material has been separated into four different subseries: evaluation of pharmaceutical products undertaken for private companies; evaluation of and...
Dates:
1970-1971